Form 4: Soleno Therapeutics Merger: Director's Ownership Changes

Soleno Therapeutics' Director Birgitte Volck reports changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Summary

• Birgitte Volck, a Director at Soleno Therapeutics Inc., has reported changes in her beneficial ownership of company securities.
• These changes are a result of the merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. (through its subsidiary Sigma Merger Sub, Inc.) which occurred on May 18, 2026.
• In connection with the merger, all outstanding shares of Soleno Therapeutics' common stock were converted into the right to receive $53.00 in cash per share.
• Similarly, all vested and unvested restricted stock units (RSUs) were cancelled and converted into the right to receive $53.00 in cash.
• Stock options held by Ms. Volck were also cancelled and exchanged for a cash payment equal to the difference between the merger consideration ($53.00) and the option's exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a completed transaction (merger) resulting in cash payouts for shareholders and option holders, rather than ongoing operational performance.

Positives

• The merger provides a cash payout of $53.00 per share for common stock and RSUs, representing a realization event for shareholders and option holders.
• All outstanding equity awards (RSUs and stock options) were addressed in the merger, leading to a cash settlement for all holders.

Negatives

• All common stock, RSUs, and stock options were cancelled as part of the merger, meaning no continued equity ownership in the combined entity for existing Soleno shareholders.
• The value received for stock options is dependent on the exercise price, with options having higher exercise prices resulting in lower cash payouts.

Risks

• The filing does not explicitly mention any ongoing risks related to the merger completion or post-merger integration, as it primarily reports on ownership changes.
• Potential risks for option holders include the possibility that the exercise price of their options might be higher than the merger consideration, resulting in no cash payout or even a net loss if not structured to avoid this.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on a completed transaction.

Industry Context

StockSavvy.ai notes that mergers and acquisitions are common in the biopharmaceutical industry as companies seek to consolidate pipelines, gain market share, or achieve economies of scale. This transaction signifies an exit for Soleno Therapeutics shareholders.

Stakeholder Impact

• Shareholders: Will receive $53.00 in cash per share, realizing their investment.
• Option Holders: Will receive cash based on the difference between the merger consideration and their option's exercise price.
• Employees: Those holding RSUs or options will receive cash settlements as described.
• Creditors: The impact on creditors is not detailed in this filing, but typically mergers involve assumption of liabilities or repayment of debt.

Next Steps

• Shareholders and option holders will receive cash payments as per the merger agreement.
• Soleno Therapeutics will cease to exist as an independent publicly traded entity.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Form 4, Beneficial Ownership, Director, Stock Options, RSUs, SEC Filing, Corporate Actions